ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO1115

Independent of Moderate-Vigorous Physical Activities (MVPA), Light-Intensity Physical Activities (LPA) Are Associated with Lower Risk of Heart Failure (HF) in CKD

Session Information

Category: Health Maintenance, Nutrition, and Metabolism

  • 1500 Health Maintenance, Nutrition, and Metabolism

Authors

  • Steiner, William Paul, University of Utah Health, Salt Lake City, Utah, United States
  • Boucher, Robert E., University of Utah Health, Salt Lake City, Utah, United States
  • Derington, Catherine G., University of Utah Health, Salt Lake City, Utah, United States
  • Welling, Kamryn L., University of Utah Health, Salt Lake City, Utah, United States
  • Ence, Thomas Steven, University of Utah Health, Salt Lake City, Utah, United States
  • Beddhu, Srinivasan, University of Utah Health, Salt Lake City, Utah, United States
Background

Whether higher LPA is associated with lower the risk of HF in CKD is not well defined.

Methods

A wrist worn accelorometer was used in UK Biobank to measure physical activity levels in 103,615 participants between 2013 to 2015. We included 10,843 participants with CKD and vaild accelerometry data. We also excluded those with HF at baseline. CKD was defined as 1. eGFR < 60, 2. eGFR >=60 with urine ACR > 30 mg/g, or 3. CKD ICD codes prior to accelerrmetery measurement. Based on wear time and sleep duration, awake wear time was calculated. LPA and MVPA durations/ awake hour is calculated as min/hr. Participants were followed until 10/31/2022 for incident HF (ICD10-defined). In multivariate Cox regression, we related tertiles of LPA and MVPA with the subsequent incidence of HF adjusted for demographics, smoking, CAD, T2D, lung disease, baseline BMI and SBP.

Results

Of the 10,843 participants included, mean age was 62 ± SD years; 51% were female, and 96% white. Baseline prevalence of stage 2 CKD was 87% and stage 3 CKD or greater 13%. LPA mean was 20 ± 6 min/hr and MVPA was 2.0(0.9, 3.6) min/hr. There were 378 HF events/ 82,935 years of follow-up. As shown in the figure, higher levels of both LPA and MVPA were associated with lower risk of HF.

Conclusion

Both LPA and MVPA are indepenently associated with lower risk of HF in CKD. Interventions targeting light intensity activities might reduce the risk of HF in CKD.

Baseline characteristicsLPA<17 min/hr
N=3382
LPA 17-22 min/hr
N=3480
LPA >22 min/hr
N=3981
Age, yr57 ± 857 ± 857 ± 8
Female, %507082
White, %969696
T2 DM, %1153
CAD, %6.33.72.5
SBP, mmHg143 ± 22141 ± 21141 ± 22
BMI, kg/m228.3 ± 5.826.4 ± 4.625.3 ± 4.4
MVPA1.8 (0.7,3.5)2.2 (1.0,3.7)2.1 (1.1,3.5)

Digital Object Identifier (DOI)